ReviewBlood cancer journal2019
Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma.
Review in Blood cancer journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05834426 (Omic Technologies Applied to the Study of Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Omic Technologies Applied to the Study of Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Novel concepts of cell-of origin in neuroendocrine neoplasms.Virchows Archiv : an international journal of pathology · 2026Review
- HIV-Associated Lymphomas: Updates from Pathogenesis to Treatment Strategies.Current HIV research · 2026Review
- Expression and Clinical Significance of CXCR5 and LAG-3 on Peripheral Blood CD8The Kaohsiung journal of medical sciences · 2025Article
- Tumor gene expression signatures associated with outcome in large B-cell lymphoma treated with CD19-directed CAR T-cell therapy (axicabtagene ciloleucel).Frontiers in oncology · 2025Article
- Immune Characteristics and Immunotherapy of HIV-Associated Lymphoma.Current issues in molecular biology · 2024Review
- Adherence to guidelines-recommended diagnostic testing was associated with overall survival in patients with diffuse large B-cell lymphoma after rituximab-based treatment: an observational cohort study.Journal of cancer research and clinical oncology · 2023Observational
- Evaluation of a convolution neural network for baseline total tumor metabolic volume on [European radiology · 2023Article
- Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells.Frontiers in immunology · 2023Article
- Hepatitis B Virus and B-cell lymphoma: evidence, unmet need, clinical impact, and opportunities.Frontiers in oncology · 2023Review
- An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy.EJHaem · 2022Article
- Independent Drug Action in Combination Therapy: Implications for Precision Oncology.Cancer discovery · 2022Review
- The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice.Frontiers in oncology · 2022Review
- Expression of NBioengineered · 2021Article
- Advances in Lymphoma Molecular Diagnostics.Diagnostics (Basel, Switzerland) · 2021Review
- Systemic immune inflammation index, ratio of lymphocytes to monocytes, lactate dehydrogenase and prognosis of diffuse large B-cell lymphoma patients.World journal of clinical cases · 2021Article
- Metabolic Swifts Govern Normal and Malignant B Cell Lymphopoiesis.International journal of molecular sciences · 2021Review
- Primary pancreatic diffuse large B-cell lymphoma, activated B-cell subtype, diagnosed by endoscopic ultrasound-guided fine needle aspiration-A case report and review of the literature.Clinical case reports · 2021Article
- Article
- Prognostic impact of abdominal lymph node involvement in diffuse large B-cell lymphoma.European journal of haematology · 2020Article
- Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma.American journal of hematology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precision medicine is modernizing strategies for clinical study design to help improve diagnoses guiding individualized treatment based on genetic or phenotypic characteristics that discriminate between patients with similar clinical presentations. Methodology to personalize treatment choices is being increasingly employed in clinical trials, yielding favorable correlations with improved response rates and survival. In patients with diffuse large B-cell lymphoma (DLBCL), disease characteristics and outcomes may vary widely, underscoring the importance of patient classification through identification of sensitive prognostic features. The discovery of distinct DLBCL molecular subtypes based on cell of origin (COO) is redefining the prognosis and treatment of this heterogeneous cancer. Owing to significant molecular and clinical differences between activated B-cell-like (ABC)- and germinal center B-cell-like (GCB)-DLBCL subtypes, COO identification offers opportunities to optimize treatment selection. Widespread adoption of COO classification would greatly improve treatment and prognosis; however, limitations in interlaboratory concordance between immunohistochemistry techniques, cost, and availability of gene expression profiling tools undermine universal integration in the clinical setting. With advanced methodology to determine COO in a real-world clinical setting, therapies targeted to specific subtypes are under development. The focus here is to review applications of precision medicine exemplified by COO determination in DLBCL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.